Vertex misses quarterly results on weaker-than-expected demand for cystic fibrosis drug
(Reuters) -Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday, due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta. However, the drugmaker raised the lower end of its revenue forecast as it looks to …